2M7C Stock Overview
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
China Medical System Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.46|
|52 Week High||HK$2.30|
|52 Week Low||HK$1.08|
|1 Month Change||8.15%|
|3 Month Change||4.29%|
|1 Year Change||-35.40%|
|3 Year Change||86.94%|
|5 Year Change||-1.88%|
|Change since IPO||414.57%|
Recent News & Updates
|2M7C||DE Pharmaceuticals||DE Market|
Return vs Industry: 2M7C underperformed the German Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: 2M7C underperformed the German Market which returned -22% over the past year.
|2M7C Average Weekly Movement||7.7%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DE Market||10.2%|
|10% least volatile stocks in DE Market||2.9%|
Stable Share Price: 2M7C is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 2M7C's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company’s products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications.
China Medical System Holdings Fundamentals Summary
|2M7C fundamental statistics|
Is 2M7C overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2M7C income statement (TTM)|
|Cost of Revenue||CN¥2.09b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||1.23|
|Net Profit Margin||36.19%|
How did 2M7C perform over the long term?See historical performance and comparison
4.6%Current Dividend Yield
Is 2M7C undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2M7C?
Other financial metrics that can be useful for relative valuation.
|What is 2M7C's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 2M7C's PE Ratio compare to its peers?
|2M7C PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
DMP Dermapharm Holding
PSG PharmaSGP Holding
MRK MERCK Kommanditgesellschaft auf Aktien
2M7C China Medical System Holdings
Price-To-Earnings vs Peers: 2M7C is good value based on its Price-To-Earnings Ratio (8.6x) compared to the peer average (21.5x).
Price to Earnings Ratio vs Industry
How does 2M7C's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 2M7C is good value based on its Price-To-Earnings Ratio (8.6x) compared to the German Pharmaceuticals industry average (22.5x)
Price to Earnings Ratio vs Fair Ratio
What is 2M7C's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||8.6x|
|Fair PE Ratio||31.4x|
Price-To-Earnings vs Fair Ratio: 2M7C is good value based on its Price-To-Earnings Ratio (8.6x) compared to the estimated Fair Price-To-Earnings Ratio (31.4x).
Share Price vs Fair Value
What is the Fair Price of 2M7C when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2M7C (€1.46) is trading below our estimate of fair value (€4.57)
Significantly Below Fair Value: 2M7C is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 2M7C is poor value based on its PEG Ratio (1.1x)
Discover undervalued companies
How is China Medical System Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2M7C's forecast earnings growth (8% per year) is above the savings rate (-0.05%).
Earnings vs Market: 2M7C's earnings (8% per year) are forecast to grow slower than the German market (8.3% per year).
High Growth Earnings: 2M7C's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2M7C's revenue (11.1% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: 2M7C's revenue (11.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2M7C's Return on Equity is forecast to be high in 3 years time (22.2%)
Discover growth companies
How has China Medical System Holdings performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2M7C has high quality earnings.
Growing Profit Margin: 2M7C's current net profit margins (36.2%) are lower than last year (36.4%).
Past Earnings Growth Analysis
Earnings Trend: 2M7C's earnings have grown by 14.6% per year over the past 5 years.
Accelerating Growth: 2M7C's earnings growth over the past year (19.2%) exceeds its 5-year average (14.6% per year).
Earnings vs Industry: 2M7C earnings growth over the past year (19.2%) exceeded the Pharmaceuticals industry 17.9%.
Return on Equity
High ROE: 2M7C's Return on Equity (23.5%) is considered high.
Discover strong past performing companies
How is China Medical System Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 2M7C's short term assets (CN¥7.4B) exceed its short term liabilities (CN¥2.1B).
Long Term Liabilities: 2M7C's short term assets (CN¥7.4B) exceed its long term liabilities (CN¥879.6M).
Debt to Equity History and Analysis
Debt Level: 2M7C has more cash than its total debt.
Reducing Debt: 2M7C's debt to equity ratio has reduced from 26% to 13.1% over the past 5 years.
Debt Coverage: 2M7C's debt is well covered by operating cash flow (148.5%).
Interest Coverage: 2M7C earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is China Medical System Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 6/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2M7C's dividend (4.62%) is higher than the bottom 25% of dividend payers in the German market (1.47%).
High Dividend: 2M7C's dividend (4.62%) is in the top 25% of dividend payers in the German market (4.53%)
Stability and Growth of Payments
Stable Dividend: 2M7C's dividends per share have been stable in the past 10 years.
Growing Dividend: 2M7C's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (40.2%), 2M7C's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (52.2%), 2M7C's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Kong Lam (56 yo)
Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...
CEO Compensation Analysis
Compensation vs Market: Kong's total compensation ($USD678.70K) is below average for companies of similar size in the German market ($USD2.46M).
Compensation vs Earnings: Kong's compensation has been consistent with company performance over the past year.
Experienced Board: 2M7C's board of directors are seasoned and experienced ( 10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Medical System Holdings Limited's employee growth, exchange listings and data sources
- Name: China Medical System Holdings Limited
- Ticker: 2M7C
- Exchange: DB
- Founded: 1995
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$30.610b
- Listing Market Cap: HK$3.697b
- Shares outstanding: 2.45b
- Website: https://www.cms.net.cn
Number of Employees
- China Medical System Holdings Limited
- Island Place Tower
- Unit 2106
- North Point
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.